The Indianapolis-based drug manufacturer will report its latest earnings results before the market open on Thursday.
Analysts surveyed by Thomson Reuters are expecting the company to report earnings of 78 cents per share on revenue of $5.32 billion for the most recent quarter.
Eli Lilly reported earnings of 73 per cents per share on revenue of $5.12 billion in the year-ago period.
The Street's Jim Cramer's charitable trust, Action Alerts PLUS, recently trimmed its investment in Eli Lilly to about 1.4% of its portfolio. Shares of the company surged earlier this month when the company announced that it submitted a new drug application to the FDA for its rheumatoid arthritis treatment.
"We believe the long- term story remains intact and we continue to point to the extensive pipeline as support for future share gains, but we think it is more important to book some profits and maintain a high level of cash in the near term," Cramer and Research Director Jack Mohr said in a post on Action Alerts PLUS. "We will be actively monitoring shares of LLY in the coming days and would be buyers on any material dip given our longer- term conviction."
Shares of the company have climbed by about 13% during the last year.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "buy" with a ratings score of B. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow.
You can view the full analysis from the report here: LLY